Crossmark

The past 10 years—new hormones, new functions, new endocrine organs

Crossref DOI link: https://doi.org/10.1038/nrendo.2015.142

Published Online: 2015-09-01

Published Print: 2015-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bouillon, Roger

Drucker, Daniel J.

Ferrannini, Ele

Grinspoon, Steven

Rosen, Clifford J.

Zimmet, Paul
License Information

Text and Data Mining valid from 2015-09-01
More Information

Article History

First Online: 1 September 2015

Competing interests

: D.J.D. has served as an advisor or consultant for Arisaph Pharmaceutical, Intarcia Therapeutics, Merck Research Laboratories, MedImmune, Novo Nordisk, NPS Pharmaceutical, Receptos and Sanofi. Neither D.J.D. nor his family members hold stock directly or indirectly in any of these companies. S.G. has received research funding from Amgen, Gilead, KOWA and Theratechnologies; he has also received consulting fees from BMS, Gilead, Merck, Navidea, Takeda and Theratechnologies. P.Z. has received consulting fees from Amgen. R.B., E.F. and C.J.F. declare no competing interests.